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Abstract: Background: The effects of mental and behavioral disorders (MBD) due to 
substance use during peri-conception and pregnancy on perinatal outcomes are unclear. 
The adverse perinatal outcomes of primiparous mothers admitted to hospital with  
MBD due to substance use before and/or during pregnancy were investigated.  
Method: This study linked birth and hospital records in NSW, Australia. Subjects included 
primiparous mothers admitted to hospital for MBD due to use of alcohol, opioids or 
cannabinoids during peri-conception and pregnancy. Results: There were 304 primiparous 
mothers admitted to hospital for MBD due to alcohol use (MBDA), 306 for MBD due to 
opioids use (MBDO) and 497 for MBD due to cannabinoids (MBDC) between the  
12 months peri-conception and the end of pregnancy. Primiparous mothers admitted to 
hospital for MBDA during pregnancy or during both peri-conception and pregnancy were 
OPEN ACCESS 
Int. J. Environ. Res. Public Health 2014, 11 4992 
 
 
significantly more likely to give birth to a baby of low birthweight (AOR = 4.03,  
95%CI: 1.97–8.24 for pregnancy; AOR = 9.21, 95%CI: 3.76–22.57 both periods);  
preterm birth (AOR = 3.26, 95% CI: 1.52–6.97 for pregnancy; AOR = 4.06,  
95%CI: 1.50–11.01 both periods) and admission to SCN or NICU (AOR = 2.42,  
95%CI: 1.31–4.49 for pregnancy; AOR = 4.03, 95%CI: 1.72–9.44 both periods). 
Primiparous mothers admitted to hospital for MBDO, MBDC or a combined diagnosis 
were almost three times as likely to give birth to preterm babies compared to mothers 
without hospital admissions for psychiatric or substance use disorders. Babies whose 
mothers were admitted to hospital with MBDO before and/or during pregnancy were six 
times more likely to be admitted to SCN or NICU (AOR = 6.29, 95%CI: 4.62–8.57). 
Conclusion: Consumption of alcohol, opioids or cannabinoids during peri-conception or 
pregnancy significantly increased the risk of adverse perinatal outcomes.  
Keywords: pregnancy; perinatal outcomes; substance use; alcohol; opioids; cannabinoids 
 
1. Introduction 
The prevalence of substance use has increased markedly in the past two decades and women are not 
immune to this trend, with approximately 90% of drug abusing women being of reproductive age and 
increasingly including pregnant women [1]. Alcohol and substance use has been found to result in 
adverse perinatal outcomes including preterm birth and low birthweight which have been subsequently 
associated with long term infant morbidity and mortality [2–4]. Alcohol use during pregnancy has been 
associated with preterm birth, low APGAR scores, admission to special care nurseries (SCN) and fetal 
alcohol spectrum disorders [5–8].  
The literature suggests that opiate use is associated with a range of adverse clinical outcomes 
including preterm birth, poor growth, and increased length of hospital stay for the baby [5,9–11]. 
Neonatal outcomes from cannabis exposure has been less conclusive with a number of studies 
reporting adverse effects including low birthweight [12] and preterm birth [12] and other studies 
dispute these findings [13]. A population-based self-report study in the United States found cannabis 
use was not associated with low birthweight or preterm birth [13] whereas a self-report study in 
Australia found that cannabis use was associated with low birthweight, preterm labour and admission 
to neonatal intensive care unit (NICU) [12]. A recent overview of studies on prenatal cannabis 
exposure and infant outcomes has concluded that fetal development is affected by prenatal maternal 
cannabis use [14]. Polysubstance use is common among pregnant women and the effects on perinatal 
outcomes are more significant. A study in Denmark reported that polysubstance use was associated 
with poorer perinatal outcomes compared with only alcohol or with no substance exposure [15].  
The pregnancy period represents a time of significant change and adjustment in women’s lives [16]. 
However the significance of substance use during peri-conception and the risk of adverse neonatal 
outcomes are largely unknown. Substance use is often a chronic disorder where relapse is common. 
Therefore the peri-conception period may be relevant clinically to women of childbearing age.  
An admission for a mental and behavioral disorder (MBD) due to substance use in a women of 
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childbearing age may present an opportunity to identify women at risk of substance use during 
pregnancy and provide an opportunity to discuss family planning and available resources for substance 
use treatment with the view of minimising or preventing substance use and/or unplanned pregnancy.  
The majority of studies to date on substance use involve self-reported information of which the 
limitations are well documented and include under-reporting and recall bias [17]. The dispute related 
to the validity of self-reported data is no greater than in alcohol and drug research [18].  
Hospital admission records and other administrative data provide an objective measure of severe 
substance use in pregnancy and complements self-reported data and other similar methodologies. 
Population-based administrative data provide a mechanism for validation of self-reported observations 
and trend data over time. 
This study investigates women who were admitted to hospital with a primary diagnosis MBD due to 
substance use in the period 12 months before and/or during pregnancy. The aims of the study are to 
measure the impact of MBD due to substance use (alcohol, cannabinoids and opioids) necessitating 
hospital admission before and during pregnancy on perinatal outcomes and to analyse the impact of 
poly-substance use of MBD due to alcohol, opioids and cannabinoids on pregnancy outcomes. 
2. Methods  
2.1. Study Design 
This is a retrospective cohort study using population linked data. Baby birth records of primiparous 
women from 1 January 2003 to 31 December 2006 (from the New South Wales (NSW)  
Midwives Data Collection (MDC)) were linked with maternal hospital records (from the NSW 
Admitted Patients Data Collection (APDC)). About ten per cent (13,113 mothers) of women who gave 
birth (MDC records) and did not have a diagnosis of psychiatric illness and substance use were 
randomly selected as the comparison group. 
The MDC is a population-based data collection of all births in New South Wales, Australia.  
It covers all births of at least 20 weeks gestation or at least 400g birth weight in public and private 
hospitals as well as home births, and includes information on maternal characteristics, pregnancy, 
labour, delivery and perinatal outcomes. The APDC is a routinely collected census of all hospital 
separations. It includes all patient hospitalizations from NSW public and private hospitals  
(including psychiatric hospitals) and day procedures. Information on patients includes demographics, 
diagnoses and clinical procedures. Since 1999, diagnoses have been coded according to the  
10th revision of the International Statistical Classification of Diseases and Related Health Problems, 
Australian Modification (ICD-10-AM) [19]. Data linkage was performed by the Centre for  
Health Record Linkage (CHeReL) using probabilistic record linkage methods and Choicemaker 
software [20]. Linkage quality was assessed by a review from a random sample of 1,000 records. The 
false positive rate of the linkage was 0.3% and false negative less than 0.5%.  
2.2. Study Population  
The study subjects (945) included all primiparous women who gave birth in NSW between  
1 January 2003 to 31 December 2006 and were admitted to hospital with a diagnosis of mental and 
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behavioral disorders due to use of alcohol, opioids and cannabinoids in the period from the 12th month 
before pregnancy to the end of pregnancy. The comparison group included a 10% sample of 
primiparous mothers with no documented diagnosis of psychiatric illness or substance use during the 
study period. All mothers were aged between 18 and 44 years old. 
2.3. Definition 
The diagnosis of mental and behavioral disorders due to use of alcohol include principal,  
stay and other diagnoses of ICD-10-AM F10. 
The diagnosis of mental and behavioral disorders due to use of opioids include principal,  
stay and other diagnoses of ICD-10-AM F11. 
The diagnosis of mental and behavioral disorders due to use of cannabinoids include principal,  
stay and other diagnoses of ICD-10-AM F12. 
Low birthweight: birthweight of less than 2,500 grams (<2,500 grams). 
Preterm birth: birth of less than 37 weeks of gestation (<37 weeks). 
2.4. Statistical Analysis 
Logistic regression was used to measure the risk of adverse perinatal outcomes due to use of 
alcohol, opioids and cannabinoids for low birthweight, preterm birth and admission to SCN or NICU. 
Odds ratios were adjusted for maternal age, maternal country of birth, smoking status (yes/no), 
remoteness of living area, and a socioeconomic indicator (the Index of Relative Socio-economic 
Disadvantage) [21], pre-existing maternal diabetes, pre-existing maternal hypertension,  
pregnancy complications (pre-eclampsia, gestational diabetes), method of birth, infant gender and 
fetal/neonatal death. All analyses were conducted using IBM SPSS Statistics 20. 
2.5. Ethics Approval 
This research was approved by the NSW Population & Health Services Research Ethics Committee 
and the Human Research Ethics Committee of the University of New South Wales, Sydney, Australia. 
3. Results 
From 1 January 2003 to 31 December 2006 there were 945 primiparous mothers admitted to 
hospital for a MBD due to alcohol, opioid or cannabinoid use between 12 months peri-conception 
period and the end of pregnancy in NSW. Among them, 304 primiparous mothers admitted to hospital 
for MBD due to alcohol use (MBDA), 306 primiparous mothers for MBD due to opioids use (MBDO) 
and 497 primiparous mothers for MBD due to cannabinoids (MBDC). There were 146 admissions 
were diagnoses overlapped (that it, one admission included more than one diagnosis). For example, 
there were 16 admissions for the combined diagnosis of alcohol and opioids; 52 admissions for the 
combined diagnoses of alcohol and cannabinoids; 62 admissions for the combined diagnoses of opioids 
and cannabinoids and 16 admissions for the combined diagnoses of alcohol, opioids and cannabinoids. 
The comparison group included 13,113 primiparous mothers (10%) who were not admitted to hospital 
with a diagnosis of psychiatric or substance use disorder during the study period. There were 20 birth 
Int. J. Environ. Res. Public Health 2014, 11 4995 
 
 
records with birthweight values missing (12 in comparison group and eight in hospital admission group) 
and one birth in the comparison group with a missing value for gestational age. 
3.1. Hospital Admission for Mental and Behavioral Disorders due to Substance Use  
and Perinatal Outcomes  
Logistic regression model was used for 220 mothers who were admitted to hospital with MBDA, 
212 mothers with MBDO, 367 mothers with MBDC, 146 mothers with MBD due to poly-substance 
use which refers to more than one use of alcohol, opioids and cannabinoids in the period 12 months 
before pregnancy and during pregnancy.  
The diagnoses of MBDA, MDBO, MBDC and poly-substance use before and/or during pregnancy 
on perinatal outcomes including low birthweight, preterm birth and baby admission to an NICU or 
SCN are presented in Table 1.  
Compared with mothers who were not admitted to hospital with a diagnosis of a psychiatric 
disorder or substance use, mothers admitted to hospital with an alcohol-related diagnosis of MBDA 
were almost twice as likely to give birth of babies with low birthweight (adjusted odds ratio  
AOR = 1.97, 95%CI: 1.26–3.06); mothers with MBDO and MBDC were about four times more likely 
to give birth to low birthweight babies (AOR for MBDO and MBDC were 3.72 (95%CI: 2.57–5.39), 4.31 
(95%CI: 3.20–5.82) respectively). Mothers with poly-substance use of more than one of MBDA, 
MBDO or MBDC were three times as likely to give birth to a low birthweight baby (AOR = 3.21, 
95%CI: 2.03–5.08). 
Mothers admitted to hospital with a diagnosis of MBDO, MBDC or combined diagnosis were 
almost three times as likely to give birth to preterm babies compared to mothers without hospital 
admissions for psychiatric or substance use disorders.  
Babies whose mothers were admitted to hospital with MBDO before and/or during pregnancy were 
six times as likely to be admitted to SCN or NICU (AOR = 6.29, 95%CI: 4.62–8.57). Babies whose 
mothers where admitted to hospital with MBDC or a poly-substance use diagnosis was two and four 
times more likely to be admitted to SCN or NICU respectively.  
Table 1. Mental disorder due to alcohol, opioids or cannabinoids and perinatal outcomes. 
Perinatal  
Outcomes  
Mental and Behavioral 
Disorders due to 
Substance Use 





No substance 13,101 1   1   
Alcohol * 219 2.01 1.32 3.04 1.97 1.26 3.06 
Opioids * 212 4.97 3.61 6.83 3.72 2.57 5.39 
Cannabinoids * 367 5.43 4.26 6.91 4.31 3.20 5.82 
Polysubstance b,* 146 4.02 2.68 6.01 3.21 2.03 5.08 
Preterm birth 
(<37 weeks) 
No substance 13,112 1   1   
Alcohol 220 1.28 0.79 2.05 1.29 0.78 2.15 
Opioids * 212 3.34 2.36 4.71 2.99 2.00 4.46 
Cannabinoids * 367 2.91 2.20 3.83 2.68 1.92 3.74 
Polysubstance b,* 146 3.35 2.22 5.05 2.97 1.84 4.78 
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Table 1. Cont. 
Perinatal 
Outcomes  
Mental and Behavioral 
Disorders due to  
Substance Use 
n OR 95%CI AOR 
a
 95%CI 
Admission to SCN  
or NICU 
No substance 13,113 1   1   
Alcohol 220 1.13 0.82 1.57 1.10 0.77 1.57 
Opioids * 212 6.66 5.04 8.81 6.29 4.62 8.57 
Cannabinoids * 367 2.35 1.89 2.92 2.15 1.67 2.76 
Polysubstance b,* 146 4.29 3.09 5.95 4.03 2.80 5.78 
Notes: OR: crude odds ratio. AOR: adjusted odds ratio. SCN: special care nursery; NICU: neonatal intensive 
care unit. a: Adjusted for maternal age, pre-existing maternal diabetes, pre-existing maternal hypertension, 
pregnancy complications (pre-eclampsia, gestational diabetes), maternal smoking status (yes/no),  
remoteness of living area, Index of Relative Socio-economic Disadvantage, maternal country of birth, 
delivery method, infant gender and fetal/neonatal death. b: Poly-substance refers to overlapped diagnoses 
among MBDA, MBDO and MBDC. At least two of these disorders were diagnosed in the 12-month period 
before pregnancy and during pregnancy. * Significantly associated with perinatal outcomes compared with 
non-substance use (p < 0.05). 
3.2. Hospital Admission Time for MBD and Low Birthweight 
The impact of a diagnosis of MBD due to substance use before and during pregnancy and the 
birthweight outcomes are presented in Table 2. Mothers admitted to hospital with MBDA during 
pregnancy or in both peri-conception and pregnancy periods were significantly more likely to give 
birth to a baby of low birthweight (AOR = 4.03, 95%CI: 1.97–8.24 for pregnancy; AOR = 9.21, 
95%CI: 3.76–22.57 for both periods). Admission for MBDA in peri-conception was found not to be 
significantly associated with low birthweight babies. 
Table 2. Mental and behavioral disorders due to substance use in peri-conception and 
pregnancy and low birthweight.  
Mental and Behavioral 










Lower Upper Lower Upper 
Alcohol use 
No 13,101 1   1   
Peri-conception 226 1.61 1.03 2.51 1.53 0.95 2.45 
Pregnancy * 54 4.26 2.23 8.12 4.03 1.97 8.24 
Both b,* 23 11.46 5.01 26.22 9.21 3.76 22.57 
Opioids use 
No 13,101 1   1   
Peri-conception * 62 3.21 1.67 6.19 2.27 1.10 4.71 
Pregnancy * 185 5.07 3.62 7.12 3.56 2.39 5.32 
Both * 59 7.08 4.08 12.27 5.71 3.15 10.35 
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Table 2. Cont. 
Mental and Behavioral 










Lower Upper Lower Upper 
Cannabinoids use 
No 13,101 1   1   
Peri-conception * 140 3.24 2.09 5.02 2.72 1.67 4.44 
Pregnancy * 330 6.02 4.70 7.72 4.85 3.55 6.62 
Both * 27 3.39 1.28 8.96 3.13 1.11 8.82 
Notes: OR: crude odds ratio. AOR: adjusted odds ratio. SCN: special care nursery; NICU: neonatal intensive 
care unit. a: Adjusted for maternal age, pre-existing maternal diabetes, pre-existing maternal hypertension, 
pregnancy complications (pre-eclampsia, gestational diabetes), maternal smoking status (yes/no),  
remoteness of living area, Index of Relative Socio-economic Disadvantage, maternal country of birth, 
delivery method, infant gender and fetal/neonatal death. b: Both includes the periods of 12 months  
before pregnancy and pregnancy. * Significantly associated with low birthweight compared  
with non-substance use (p < 0.05). 
Mothers admitted to hospital with MBDO before or during pregnancy, or in both periods, were at 
significantly increased risk of giving birth to a baby with low birthweight (AOR = 2.27, 95%CI: 1.10–4.71 
for peri-conception; AOR = 3.56, 95%CI: 2.39–5.32 for pregnancy and AOR = 5.71, 95%CI: 3.15–10.35 
for both periods). Similarly, mothers admitted to hospital with a diagnosis of MBDC before or during 
pregnancy, or in both periods were more likely to give birth to a low birthweight baby (AOR = 2.72, 
95%CI: 1.67–4.44 for peri-conception; AOR = 4.85, 95%CI: 3.55–6.62 for pregnancy and  
AOR = 3.13, 95%CI: 1.11–8.82 for both periods).  
3.3. Hospital Admission Time for MBD and Preterm Birth 
The impact of a diagnosis of MBD due to substance use before and during pregnancy and the 
preterm birth outcomes are presented in Table 3. Compared with mothers who were not admitted to 
hospital with a diagnosis of psychiatric disorder or substance use, mothers admitted to hospital with 
MBDA during pregnancy or in both periods were more likely to give birth to a preterm baby  
(AOR = 3.26, 95%CI: 1.52–6.97 for pregnancy; AOR = 4.06, 95%CI: 1.50–11.01 for both periods). 
Admission for MBDA in peri-conception was found not to be significantly associated with preterm births. 
The risk of a preterm birth increased significantly when mothers were admitted to hospital for 
MBDO during pregnancy or in both periods of peri-conception and pregnancy (AOR = 3.22,  
95%CI: 2.11–4.92 for peri-conception; AOR = 5.15, 95%CI: 2.76–9.63 for both periods).  
Mothers admitted to hospital with MBDC during pregnancy were more likely to give birth to preterm 
babies (AOR = 3.61, 95%CI: 2.58–5.04). Peri-conception admission for MBDO and MBDC were not 
found to be significantly associated with preterm birth however admission for MBDC during 
pregnancy was significantly associated (AOR = 3.61, 95%CI: 2.58–6.04). 
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Table 3. Mental and behavioral disorders due to substance use in peri-conception and 
pregnancy and preterm birth.  
Mental and 
Behavioral 










Low Up Low Up 
Alcohol use No 13,112 1      
 
Peri-conception 226 1.10 0.67 1.81 1.07 0.62 1.83 
Pregnancy * 55 3.38 1.74 6.56 3.26 1.52 6.97 
Both b,* 23 4.77 1.87 12.12 4.06 1.50 11.01 
Opioids use 
No 13,112       
Peri-conception 62 1.72 0.78 3.78 1.38 0.56 3.37 
Pregnancy * 185 3.73 2.61 5.32 3.22 2.11 4.92 
Both * 59 5.02 2.82 8.96 5.15 2.76 9.63 
Cannabinoids use 
No 13,112       
Peri-conception 140 1.62 0.94 2.78 1.56 0.87 2.80 
Pregnancy * 330 3.77 2.88 4.94 3.61 2.58 5.04 
Both 27 2.35 0.81 6.81 1.92 0.55 6.76 
Notes: OR: crude odds ratio. AOR: adjusted odds ratio. a: Adjusted for maternal age, pre-existing maternal 
diabetes, pre-existing maternal hypertension, pregnancy complications (pre-eclampsia, gestational diabetes), 
maternal smoking status (yes/no), remoteness of living area, Index of Relative Socio-economic Disadvantage, 
maternal country of birth, delivery method, infant gender and fetal/neonatal death. b: Both includes the 
periods of 12 months before pregnancy and pregnancy. * Significantly associated with low birthweight 
compared with non-substance use (p < 0.05). 
3.4. Hospital Admission Time for MBD and Babies’ Admission to SCN or NICU 
The impact of a diagnosis of MBD due to substance use before and during pregnancy and babies’ 
admission to SCN or NICU outcomes are presented in Table 4. Babies were more likely to be admitted 
to SCN or NICU if their mothers were admitted to hospital with MBDA during pregnancy or in both 
peri-conception and pregnancy (AOR = 2.42, 95%CI: 1.31–4.49 for pregnancy; AOR = 4.03,  
95%CI: 1.72–9.44 for both periods). Admission for MBDA in peri-conception was found not to be 
significantly associated with baby’s admission to SCN or NICU. 
The risk of admission to SCN or NICU increased significantly if the mother was admitted to 
hospital for MBDO before pregnancy, during pregnancy or in both periods (AOR = 2.53,  
95%CI: 1.48–4.32 for peri-conception; AOR = 6.89, 95%CI: 4.93–9.63 for pregnancy; AOR = 12.94, 
95%CI: 6.94–24.14 for both periods). Similarly, babies were more likely to be admitted to SCN or 
NICU if their mothers were admitted to hospital with MBDC before pregnancy, during pregnancy or in 
both periods (AOR = 1.99, 95%CI: 1.36–2.92 peri-conception; AOR = 2.84, 95%CI: 2.19–3.68  
for pregnancy; AOR = 4.83, 95%CI: 2.11–11.05 for both periods).  
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Table 4. Mental and behavioral disorders due to substance use in peri-conception and 
pregnancy and baby’s admission to SCN or NICU.  
Mental and Behavioral 










Low Up Low Up 
Alcohol use 
No 13,113 1   1   
Peri-conception 226 1.16 0.84 1.59 1.03 0.72 1.47 
Pregnancy * 55 2.45 1.41 4.25 2.42 1.31 4.49 
Both b,* 23 4.67 2.06 10.61 4.03 1.72 9.44 
Opioids use 
No 13,113 1   1   
Peri-conception * 62 2.71 1.62 4.52 2.53 1.48 4.32 
Pregnancy * 185 7.37 5.45 9.97 6.89 4.93 9.63 
Both * 59 12.57 6.98 22.62 12.94 6.94 24.14 
Cannabinoids use 
No 13,113 1   1   
Peri-conception * 140 2.17 1.52 3.08 1.99 1.36 2.92 
Pregnancy * 330 2.89 2.31 3.62 2.84 2.19 3.68 
Both * 27 6.23 2.89 13.45 4.83 2.11 11.05 
Notes: OR: crude odds ratio. AOR: adjusted odds ratio. SCN: special care nursery; NICU: neonatal intensive 
care unit. a: Adjusted for maternal age, pre-existing maternal diabetes, pre-existing maternal hypertension, 
pregnancy complications (pre-eclampsia, gestational diabetes), maternal smoking status (yes/no),  
remoteness of living area, Index of Relative Socio-economic Disadvantage, maternal country of birth, 
delivery method, infant gender and fetal/neonatal death. b: Both includes the periods of 12 months  
before pregnancy and pregnancy. *Significantly associated with low birthweight compared  
with non-substance use (p < 0.05). 
The mother’s demographic factors and characteristics for case and comparison groups is  
detailed in Table 5. 
Table 5. Characteristics of mothers with and without hospital admissions for substance use. 




Group p value 




No 12,030 275 29.16 11,755 90.01 
<0.01 Yes 1,972 668 70.84 1304 9.99 







3,055 111 11.85 2,944 22.69 
<0.01 
2 3,231 177 18.89 3,054 23.54 
3 2,541 233 24.87 2,308 17.79 
4 2,201 192 20.49 2,009 15.49 
The most 
disadvantaged group 
2,882 224 23.91 2,658 20.49 
Total 13,910 937 100 12,973 100 
Country  
of birth 
Australia 10,040 848 89.74 9,192 70.1 
<0.01 Other countries 4,018 97 10.26 3,921 29.9 
Total 14,058 945 100 13,113 100 
Int. J. Environ. Res. Public Health 2014, 11 5000 
 
 
Table 5. Cont. 




Group p value 
Mother % Mother % 
Remoteness of 
living area 
Major city 9,478 569 60.73 8,909 68.67 
<0.01 
Regional area 4,316 358 38.21 3,958 30.51 
Remote area 116 10 1.07 106 0.82 
Total 13,910 937 100 12,973 100 
Maternal age 
<20 841 178 18.84 663 5.06 
<0.01 
20–24 2,848 391 41.38 2,457 18.74 
25–29 4,385 207 21.9 4,178 31.86 
30–34 4,165 111 11.75 4,054 30.92 
35–39 1,548 47 4.97 1,501 11.45 
40–45 271 11 1.16 260 1.98 
Total 14,058 945 100 13,113 100 
Delivery 
method 




4,153 240 25.4 3,913 29.85 
Total 14,053 945 100 13,108 100 
Gestational 
diabetes 
No 13,503 930 98.41 12,573 95.88 
<0.01 Yes 555 15 1.59 540 4.12 




No 13,979 934 98.84 13,045 99.48 
=0.01 Yes 79 11 1.16 68 0.52 
Total 14,058 945 100 13,113 100 
Maternal 
hypertension 
No 13,898 938 99.26 12,960 98.83 
>0.05 Yes 160 7 0.74 153 1.17 
Total 14,058 945 100 13,113 100 
Pre-eclampsia 
No 11,757 846 94.00 10,911 92.54 
>0.05 Yes 934 54 6.00 880 7.46 
Total 12,691 900 100 11,791 100 
4. Discussion 
This study demonstrates that women who are admitted to hospital for a MBD due to substance 
abuse during pregnancy or in the peri-conception period, here defined as 12 months preceding 
pregnancy, for alcohol, opioids or cannabinoids are at significantly increased risk of giving birth to a 
baby with poorer perinatal outcomes compared to women who did not have a diagnosis of psychiatric 
illness or substance abuse. This study found more mothers were admitted to hospital with MBD due to 
alcohol use before the pregnancy period compared with during the pregnancy period.  
This suggests that some women are able to reduce or control alcohol use during pregnancy and  
is consistent with the literature.  
The detrimental effects of alcohol on a growing fetus are well established, extensive and can be  
life-long. This study found that mothers admitted to hospital with MBD due to alcohol (MBDA) during 
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pregnancy or in both peri-conception and pregnancy were more likely to have babies there were low 
birthweight, preterm and be admitted to SCN or NICU. The risk increased when mothers had  
a hospital admission for MBDA during pregnancy, and both before and during pregnancy.  
In this study, alcohol use both during and before pregnancy was found to result in a synergistic effect 
with an increased risk of nearly 10 times on birthweight of the baby. Studies supporting this have 
observed that newborns exposed primarily to alcohol in utero were at a significant risk of being born 
low birthweight [15] and that the level of maternal drinking prior to pregnancy was found to be 
significantly related to preterm birth [22] suggesting alcohol consumption in the peri-conception 
period and during pregnancy may result in significant adverse perinatal outcomes.  
For babies whose mother was admitted to hospital with a diagnosis of MBD due to opioids 
(MBDO) in both peri-conception and pregnancy periods the increased risk of admission to SCN  
or NICU was more than the sum of the effects of either peri-conception or pregnancy.  
This indicates that opioid use before and during pregnancy has a synergistic effect on perinatal 
outcomes. Opiate use in the peri-conception and pregnancy periods significantly increased the risk of 
giving birth to a low birthweight baby. Long-term abstinence for opiate users is unusual and agonist 
treatment is advised over detoxification for pregnant women [23] which may be a contributing factor 
to the increased risk of adverse perinatal outcomes in this study for those admitted with MBDO 
compared to the rest of the cohort who may undergo detoxification. 
This study found that cannabinoids use during pregnancy increased the risk of a low birthweight 
baby, preterm birth and admission to SCN or NICU. This finding was consistent with previous studies 
suggesting cannabinoids can adversely affect perinatal outcomes [12,14]. Cannabinoids are often 
mixed with tobacco when smoked and may confound the detrimental effects of use of this drug. 
It is well established that dependent substance users are often dependent on other drugs. A study of 
women who were found by objective measure to have heavy alcohol use during pregnancy were also 
significantly more likely to use other drugs of abuse [24]. This study found poly-substance use 
significantly increased the risk of low birthweight, preterm birth and admission to SCN or NICU. 
These results are similar to a study that found women with poly-drug use were at increased risk of 
giving birth to a pre-term baby, low birthweight baby or baby with neonatal abstinence syndrome 
compared to alcohol alone [15]. A study found that pregnant women who used drugs and alcohol were 
less likely to cease substance use compared to pregnant women who used drugs or alcohol alone [25]. 
Pregnant women who receive no antenatal care may be at higher risk for substance use and  
poly-substance use with a study finding 52% of unbooked women positive for cocaine and 23% of 
these positive for poly-substance use [26] which could provide an indicator for clinicians. These results 
suggest that women with poly-substance use may find reducing or ceasing substance use more difficult 
and the effect on adverse perinatal outcomes more significant. This group of women proposes  
a particular challenge to healthcare providers. 
The results of this study suggest that peri-conception opioids and cannabinoids significantly 
increased the risk of low birthweight and admission to SCN or NICU. A study based on self-reported 
data found that high levels of alcohol and illicit drug use in the peri-conception period were predictors 
for continuation during pregnancy compared to moderate use [25] suggesting that women with heavy 
substance use are at significant risk of substance use during pregnancy. A maternal mental health study 
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concluded that the period before pregnancy and during pregnancy is a sensitive developmental period 
for both the mother and baby for future emotional, behavioural and mental development [27].  
The results from this study indicate that the peri-conception period may be an important period and 
affect perinatal outcomes. These results have clinical implications that suggest substance use history 
should be assessed in all pregnant women and appropriate management instituted. In the first instance, 
the clinical implications are that women of reproductive age admitted for MBD due to substance use 
should be proactively offered family planning options before discharge from hospital and a follow up 
plan due to the markedly increased risk of substance use during pregnancy. Women of reproductive 
age admitted for MBD due to substance use should be counselled on the increased risk of adverse 
perinatal outcomes if she became pregnant. 
The population in this study was women admitted to hospital for MBD due to substance abuse 
before or in the peri-conception period which suggests the illness was significant enough to require 
hospital admission. Research on this population is not extensive and therefore the effects of drug 
exposure before and during pregnancy are still not fully understood and further research on this 
population is warranted. From a public health perspective, repeating this study in five to ten years with 
contemporary data would provide some interesting insights into the trends of women admitted to 
hospital with an MBD due to substance use to determine if there is an increase in the number of 
admissions. This method of surveillance research can provide insights into population trends and 
whether public health prevention strategies should be implemented. Future research will be conducted 
on the characteristics of these women to determine and may provide important clinical indications for 
women with substance use issues who may be at increased risk of giving birth to a baby with poor 
neonatal outcomes.  
This study examined perinatal outcomes from mothers with a history of inpatient admission for 
MBD due to substance abuse and these results may not be generalised to those with MBD who are not 
hospitalised. These results are more likely to reflect women with relatively heavy use of substances 
that result in hospitalisation and it would be of value in future studies to have community based data 
(non-hospital admission) for comparison. 
This study population is likely to be significantly different to a population who may respond to 
surveys or provide accurate self-reported information and comparisons with research using this 
methodology should take this into account. Population data provides an objective measure of substance 
use and complements survey and self-reported data which has limitations. 
These results provide clinical and epidemiological evidence that suggest women admitted for a 
MBD due to substance use during peri-conception or during pregnancy are at increased risk of giving 
birth to baby with adverse perinatal outcomes. These results suggest that women of reproductive age 
admitted with an MBD due to substance use should be appropriately managed at discharge with 
information on the perinatal outcome risks and should be managed with substance use treatment and 
family planning options. This study also provides a quantitative analysis of how many women were 
admitted to hospital in NSW for an MBD due to substance use and the risk to perinatal outcomes.  
  




The scope of this study was limited to women admitted to hospital with mental and behavioral 
disorders due to psychoactive substances. There is a well-established relationship between substance 
use and other forms of psychiatric illness and the interplay of these conditions is complex.  
The individual effects of substance use or mental and behavioral disorders as well as the interplay 
between substance use and mental illness will be studied further in future. 
A limitation of this study is the lack of information on the level of exposure of alcohol, 
cannabinoids and opioids in the peri-conception and pregnancy periods. In addition, women admitted 
to hospital with MBD due to substance use are likely to differ significantly from other women  
who may use alcohol and illicit substances before and during pregnancy and not be admitted to 
hospital with MDB, further investigation into substance use and perinatal outcomes is warranted. 
5. Conclusions  
Severe consumption of alcohol, opioids or cannabinoids before and during pregnancy significantly 
increased the adverse pregnancy outcomes. Attention should be extended from pregnancy to  
peri-conception for preventing or reducing substance use. 
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